ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.
Akums Drugs and Pharmaceuticals scheduled a board meeting for August 8, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Akums Drugs and Pharmaceuticals' subsidiary will acquire Oriflame India's manufacturing business for ₹56 Crore. This deal expands Akums' manufacturing capacity in cosmetics and wellness products.
Akums Drugs and Pharmaceuticals Ltd filed its quarterly shareholding pattern, noting the removal of two entities from the promoter group due to their legal dissolution.
Akums Drugs and Pharmaceuticals concluded its 22nd AGM. Shareholders considered financial results, dividend declarations, and director re-appointments during the meeting.
The First Appellate Authority set aside a Rs.3.59 Crore penalty against Akums' subsidiary, Maxcure Nutravedics. This reversal follows an error in shipping addresses in 2025.
Akums reported a Rs.0.36 Crore penalty on its subsidiary, now set aside by an appellate authority. The company confirmed no financial impact from this regulatory matter.
Akums Drugs' subsidiaries received ₹22.27 Crore in income tax demands regarding historical expenditure disallowances. The company plans to appeal, citing the demands as legally unsustainable.
Akums reported FY26 revenue of ₹4,359 Cr (up 5.8%) and adjusted EBITDA of ₹522 Cr (up 13.3%). Strategy focuses on international CDMO expansion and margin improvement in API/Generic segments.
Akums Drugs received income tax assessment orders totaling ₹133.75 Crore for the 2018-2025 block period. The company plans to appeal these unsustainable demands.
Akums delivered a resilient FY26 with 5.8% revenue growth, navigating high raw material inflation and soft domestic demand through double-digit volume growth in its core CDMO segment.
Akums Drugs resumed 100% operations following a four-day disruption at Haridwar sites. The incident delayed ₹20 Crore in supply, but production loss recovery is expected.
Akums Drugs and Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The filing confirms adherence to SEBI listing and disclosure regulations.
Akums Drugs resumed over 70% of Haridwar operations following industry-wide labor unrest. Normalcy is being restored with local authorities after disruptions triggered by minimum wage reviews.
Akums Drugs and Pharmaceuticals appointed Mahajan & Aibara LLP as Internal Auditors for twelve months. The firm brings extensive multidisciplinary expertise to the company's internal control systems.
Akums Drugs and Pharmaceuticals re-appointed M/s. Balwinder & Associates as Cost Auditors for 12 months. The decision strengthens the company's regulatory compliance and cost oversight.
Akums Drugs appointed V Jagannathan and announced the cessation of Arvind Srivastava as Senior Management Personnel. These leadership changes are effective from May 14, 2026.
Akums delivered strong FY26 performance with 7.6% income growth and 14.5% EBITDA margins, driven by CDMO volume momentum despite API price erosion.
Akums Drugs and Pharmaceuticals Limited released its monitoring agency report for the March 2026 quarter. It confirms utilization of ₹680.00 Crore IPO proceeds with no deviations.
Akums Drugs reported ₹1,158 Crore Q4 revenue, marking 9.7% growth. Strong performance in CDMO business drove significant margin improvement and profitability for FY26.
Akums Drugs reported temporary operational disruptions at its Haridwar plants due to labor unrest. Management is actively negotiating with workers and local authorities to resolve the issue.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,158 Cr (+9.7% YoY) and net profit of ₹81.3 Cr (-45.7% YoY) for Q4 FY26.
Akums Drugs approved its FY26 audited financial results and recommended a total dividend of ₹3.00 per share. The move reflects board confidence in financial performance.
Akums Drugs scheduled a board meeting for May 14, 2026, to approve annual financial results. The board will also consider recommending a dividend for F.Y. 2025-26.